Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial

被引：2

作者：

Weisel, Katja ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Paner, Agne ^{[4
]}

Engelhardt, Monika ^{[5
]}

Taylor, Fiona ^{[6
]}

Lord-Bessen, Jennifer ^{[7
]}

Yao, David ^{[7
]}

Yip, Christine ^{[8
]}

Greenwood, Mike ^{[8
]}

Tang, Jackson ^{[7
]}

Cavo, Michele ^{[9
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Univ Navarra Clin, Pamplona, Spain

[4] Rush Univ Med Ctr, Chicago, IL USA

[5] Univ Med Ctr Freiburg, Freiburg, Germany

[6] Adelphi Values, Boston, MA USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Adelphi Values, Bollington, England

[9] Bologna Univ, IRCCS Azienda Osped Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1662

引用

页数：6

共 50 条

[1] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Weisel, Katja
Dimopoulos, Meletios A.
San-Miguel, Jesus
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Lord-Bessen, Jennifer
Yip, Christine
Greenwood, Mike
Tang, Jackson
Cavo, Michele
HEMASPHERE, 2023, 7 (03): : E843
[2] Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
Weisel, Katja
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Cocks, Kim
Popa-McKiver, Mihaela
Chen, Clara
Cavo, Michele
BLOOD, 2019, 134
[3] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
Raab, Marc-Steffen
Dimopoulos, Meletios
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
Leblanc, Richard
Suzuki, Kenshi
Richardson, Paul G.
Mckiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
[4] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Dimopoulos, Meletios A.
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc S.
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +
[5] ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)
Raab, M. S.
Dimopoulos, M.
Dytfeld, D.
Grosicki, S.
Moreau, P.
Takezako, N.
Hori, M.
Leleu, X.
LeBlanc, R.
Suzuki, K.
Richardson, P. G.
Popa McKiver, M.
Jou, Y. -M.
Yao, D.
Das, P.
San-Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 87 - 87
[6] Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
Weisel, Katja
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Cocks, Kim
Espensen, Ashlee
Popa-McKiver, Mihaela
Chen, Clara
Cavo, Michele
BLOOD, 2018, 132
[7] Elotuzumabplus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial
Dimopoulos, Meletios-Athanasios
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S143 - S144
[8] Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study
Hori, Mitsuo
Takezako, Naoki
Sunami, Kazutaka
Ito, Shigeki
Kuroda, Junya
Popa-McKiver, Mihaela
Jou, Ying-Ming
Shelat, Suresh G.
Miyoshi, Masafumi
Suzuki, Kenshi
BLOOD, 2018, 132
[9] Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM): efficacy results after additional follow-up of the phase 2, randomized ELOQUENT-3 study
Raab, M. S.
Dimopoulos, M. A.
Dytfeld, D.
Grosicki, S.
Moreau, P.
Takezako, N.
Hori, M.
Leleu, X.
LeBlanc, R.
Suzuki, K.
Richardson, P. G.
McKiver, Popa M.
Jou, Y. -M.
Shelat, S. G.
Robbins, M.
Rafferty, B.
San-Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 192 - 193
[10] Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study
Dimopoulos, Meletios A.
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc S.
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Shelat, Suresh G.
Robbins, Michael
Rafferty, Brian
San-Miguel, Jesus
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E164 - E165

← 1 2 3 4 5 →